Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is seeking grant applications to investigate the mechanisms by which incretin mimetics impact cancer risk. The goal of this funding announcement is to promote preclinical and patient-based studies examining the relationship between incretin mimetics and cancer risk. Key aspects of this opportunity include: * Investigating the mechanisms of how incretin mimetics influence cancer risk * Examining the dynamic changes caused by these agents * Drawing talented scientists to investigate the mechanisms of how these agents impact cancer risk * Focusing on the longer-term outcomes, such as cancer risk, rather than shorter-term outcomes like weight loss and diabetes. Some key points to consider are: • The proposed research should focus on the mechanisms by which incretin mimetics impact cancer risk • The research should be preclinical or patient-based • The goal is to draw talented scientists to investigate the mechanisms of how these agents influence cancer risk • The funding announcement is twofold, aiming to promote research and draw talented scientists to the field.